Intra-Cellular Therapies, Inc. (ITCI) Financials

$131.87

south_east
-$0.05 (-0.04%)
Day's range
$131.84
Day's range
$131.98

ITCI Income statement / Annual

Last year (2024), Intra-Cellular Therapies, Inc.'s total revenue was $680.85 M, an increase of 46.62% from the previous year. In 2024, Intra-Cellular Therapies, Inc.'s net income was -$74.68 M. See Intra-Cellular Therapies, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $680.85 M $464.37 M $249.13 M $81.71 M $22.53 M $60,613.00 $0.00 $245,837.00 $330,702.00 $91,364.00
Cost of Revenue $56.96 M $33.75 M $20.44 M $8.03 M $1.90 M $477,121.00 $368,673.00 $79.42 M $93.83 M $139,626.00
Gross Profit $623.89 M $430.63 M $228.69 M $73.67 M $20.64 M -$416,508.00 -$368,673.00 -$79.17 M -$93.50 M -$48,262.00
Gross Profit Ratio 0.92 0.93 0.92 0.9 0.92 -6.87 0 -322.06 -282.73 -0.53
Research and Development Expenses $236.12 M $180.14 M $134.72 M $88.85 M $65.78 M $89.12 M $132.17 M $79.42 M $93.83 M $87.72 M
General & Administrative Expenses $0.00 $317.66 M $272.98 M $190.11 M $150.06 M $64.95 M $30.10 M $23.67 M $24.76 M $18.19 M
Selling & Marketing Expenses $0.00 $92.20 M $85.80 M $82.50 M $36.30 M $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $504.49 M $409.86 M $358.78 M $272.61 M $186.36 M $64.95 M $30.10 M $23.67 M $24.76 M $18.19 M
Other Expenses $0.00 $0.00 -$1.18 M -$2.10 M -$282,226.00 $0.00 $0.00 -$245,837.00 -$330,702.00 -$60,705.00
Operating Expenses $740.61 M $590.01 M $492.32 M $359.36 M $251.86 M $154.07 M $162.27 M $103.09 M $118.59 M $105.91 M
Cost And Expenses $797.57 M $623.75 M $512.76 M $367.40 M $253.76 M $154.07 M $162.27 M $103.09 M $118.59 M $105.91 M
Interest Income $42.52 M $20.34 M $7.38 M $1.57 M $4.24 M $6.29 M $7.14 M $4.01 M $2.94 M $1.02 M
Interest Expense $0.00 $0.00 $7.38 M $0.00 $0.00 $0.00 $0.00 $0.00 $36,781.00 $0.00
Depreciation & Amortization $0.00 $528,000.00 $656,000.00 $533,360.00 $528,118.00 $477,121.00 $368,673.00 $213,872.00 $196,872.00 $139,626.00
EBITDA -$116.72 M -$158.85 M -$262.97 M -$285.16 M -$230.70 M -$153.53 M -$161.90 M -$102.63 M -$115.13 M -$104.65 M
EBITDA Ratio -0.17 -0.34 -1.06 -3.49 -10.24 -2533.03 0 -417.46 -348.13 -1145.44
Operating Income Ratio -0.17 -0.34 -1.06 -3.5 -10.26 -2540.9 0 -418.33 -357.6 -1158.16
Total Other Income/Expenses Net $42.52 M $20.34 M $7.38 M $1.57 M $4.24 M $6.29 M $7.14 M $4.01 M $2.90 M $1.02 M
Income Before Tax -$74.20 M -$139.04 M -$256.25 M -$284.12 M -$226.99 M -$147.72 M -$155.13 M -$98.83 M -$115.36 M -$104.79 M
Income Before Tax Ratio -0.11 -0.3 -1.03 -3.48 -10.07 -2437.11 0 -402.03 -348.84 -1146.97
Income Tax Expense $473,000.00 $636,000.00 $6,000.00 $5,631.00 $13,513.00 $1,600.00 $1,600.00 -$1.06 M $1.07 M $1,600.00
Net Income -$74.68 M -$139.67 M -$256.26 M -$284.13 M -$227.01 M -$147.72 M -$155.13 M -$97.77 M -$116.43 M -$104.79 M
Net Income Ratio -0.11 -0.3 -1.03 -3.48 -10.08 -2437.14 0 -397.72 -352.06 -1146.99
EPS -0.72 -1.46 -2.72 -3.5 -3.23 -2.68 -2.84 -2.12 -2.69 -2.91
EPS Diluted -0.72 -1.46 -2.72 -3.5 -3.23 -2.68 -2.84 -2.12 -2.69 -2.91
Weighted Average Shares Out $103.13 M $95.88 M $94.05 M $81.25 M $70.36 M $55.19 M $54.71 M $46.18 M $43.24 M $36.01 M
Weighted Average Shares Out Diluted $103.13 M $95.88 M $94.05 M $81.25 M $70.36 M $55.19 M $54.71 M $46.18 M $43.24 M $36.07 M
Link